Summary
After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.
This is a preview of subscription content, log in via an institution to check access.
References
Alberts DS, Moon TE, Stephens RA, Wilson H, Oishi N, Hilgers RD, O'Toole R, Thigpen JT (1979) Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: A preliminary report of a Southwest Oncology Group Study. Cancer Treat Rep 63:325
Bruckner HW, Wallach RC, Kabakow B, Greenspan EM, Gusberg SB, Holland JF (1978) cis-Platinum (DDP) for combination chemotherapy of ovarian carcinoma: Improved response rates and survival. Proc Am Assoc Cancer Res 19:373
Decker DG, Malkasian GD, Taylor WF (1975) Prognostic importance of histologic grading in ovarian carcinoma. Natl Cancer Inst Monogr 42:9
De Palo GM, De Lena M, Di Re F, Luciani L, Valagussa D, Bonadonna G (1975) Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 141:899
Edmonson JH, Fleming TR, Decker DG, Malkasian GD, Jorgensen EO, Jefferies JA, Webb MJ, Kvols LK (1979) Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep 63:241
Ehrlich CE, Einhorn LH, Morgan JL (1978) combination chemotherapy of ovarian carcinoma with cis-diamminedichloroplatinum (CDDP), adriamycin (ADR) and cytoxan (CTX). Proc Am Assoc Cancer Res 19:379
Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101
Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon LJ (1976) Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: A phase II trial. Cancer Treat Rep 60:77
Mangioni C, Bolis G, Natale N, Morasca L (1976) Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer. Eur J Cancer 12:353
Musumeci R, Banfi A, Bolis G, Candiani GB, De Palo G, Di Re F, Luciani L, Lattuada A, Mangioni C, Mattioli G, Natale N (1977) Lymphangiography in patients with ovarian epithelial cancer. Cancer 40:1444
Parker LM, Lockich JJ, Griffiths CT, Frei E III (1975) Adriamycin-cyclophosphamide therapy in ovarian cancer. Proc Am Assoc Cancer Res 16:263
Turbow MM, Fuks Z, Glatstein E (1978) Chemotherapy of ovarian carcinoma: Randomization between melphalan and adriamycin-cyclophosphamide. Proc Am Assoc Cancer Res 19:394
Vogl SE, Berenzweig M, Kaplan BH, Moukhtar M, Bulkin W (1979) The CHAD and HAD regimens in advanced ovarian cancer: Combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin and cis-dichlorodiammine platinum (II). Cancer Treat Rep 63:311
Young RC, Canellos GP, Chabner BA, Schein FS, Hubbard SP, De Vita VT (1974a) Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high-dose cyclophosphamide. Gynecol Oncol 2:489
Young RC, Hubbard SP, De Vita VT (1974b) The chemotherapy of ovarian cancer. Cancer Treat Rev 1:99
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, De Vita VT (1978) Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (l-PAM) versus combination chemotherapy. N Engl J Med 299:1261
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bolis, G., Bortolozzi, G., Carinelli, G. et al. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. Cancer Chemother. Pharmacol. 4, 129–132 (1980). https://doi.org/10.1007/BF00254034
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254034